Sign in
857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)
Journal article   Open access  Peer reviewed

857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)

Sikander Ailawadhi, Asher Chanan-Khan, Jennifer L. Peterson, Patrick J. Stiff, E. Ibrahim, Damian J. Green, J. Longcor, Katherine Oliver, M.F. Brown, John Friend, …
Annals of Oncology, Vol.32
2021
url
https://lens.org/120-144-894-836-839View
url
https://www.annalsofoncology.org/article/S0923-7534(21)02364-4/fulltextView
url
https://doi.org/10.1016/j.annonc.2021.08.150View
Published (Version of record) Open

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

undefined

Source: InCites

Details